List of Biotech, Pharmaceutical & Life Sciences companies in Connecticut - 73

Allyx Therapeutics is a clinical stage biotechnology company aiming to develop disease modifying therapies for Alzheimer's and Parkinson's. They are developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease.

Altucell, Inc. is a cellular engineering and biotech company backed by sound research and science focused on fulfilling a large "unmet need" in cell, molecular and regenerative therapy for treatment of Diabetes and other autoimmune and neurodegenerative diseases. The company’s proprietary and unique technology overcomes the major barriers to transplantation by a novel strategy utilizing patented micro-encapsulation technology, enabling a transplantable, cell-based therapy that avoids detection and rejection by the immune system.

Red Cross Blood Services is a Hospital and Health Care company located in 78 Eastern Blvd Ste 3, Glastonbury, Connecticut, United States.

ApiJect Systems, Corp. a medical technology company whose device development platform will make the safety and performance advantages of single-use prefilled syringes affordable. The ApiJect Platform enables pharmaceutical and biotech companies to design scalable prefilled injectors and efficiently fill-finish them with their injectable drug products. This can be done either on one of their own ApiJect-licensed Blow-Fill-Seal packaging lines or at one of our world-class manufacturing partners.

Aponia Laboratories, Inc. was founded by Robert Boolbol, M.D. and Kenneth Corroon in 2010 to develop and introduce a safe and over-the-counter pain mitigation products.

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG

ARVYS Proteins Inc. is a Contract Research Organization (CRO) that Specializes in Custom Protein Services for Drug Discovery and Life Science Research. Our strong integrated expertise in protein biochemistry, working experience with various recombinant expression systems and protein classes, up-to-date knowledge in protein technologies, enable us to become a reliable and resourceful partner for our clients. We help at any stage of a protein project. Our goal is to become your preferred outsourcing choice for Protein Services and we will work hard to earn your business. Maximize Project Success with Our Expert Protein Services! Protein Expression - generation of heterologous recombinant proteins in multiple expression systems. Fermentation & Cell Culture - bacterial, yeast, insect and mammalian biomass production for scale up processes. Protein Purification - homogeneous and well-characterized preparations save time, effort and resources. Protein Characterization - Customized design to address specific protein characterization goals. Functional Assays & Assay Development - Protocols with detection by UV-Vis, fluorescence or luminescence spectroscopy. ELISA Development - from selection of assay components to development of a working protocol. Protein Labeling & Conjugation - development of strategies to maximize functionality of modified proteins. Endotoxin Removal & Testing - expert service in less than 1 week. Antibody Development & Production - from generation of antigen to characterization of antibodies.

Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Azitra, Inc. is a preclinical stage biotechnology company harnessing the power of the microbiome to treat skin disease. The Company was founded in 2014 by scientists from Yale University and works with world-leading scientists in dermatology, microbiology, and genetic engineering to advance its programs in atopic dermatitis and targeted orphan indications. For more information visit www.azitrainc.com.

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

BiologicsMD is developing novel therapeutics and therapeutic-device combinations for the treatment of hair-loss and bone disorders. The company's portfolio of hair cycle stimulators (HCS) are first-in-class treatments that hold the promise to restore hair and prevent hair loss in conditions of alopecia. The core technology relies on targeting physiologically active agents to Type l collagen found in skin and bone. BiologicsMD's targeted approach minimizes off-target effects and increases the time of exposure at the sites of function.

BioSig Technologies is a medical technology company focused on deciphering the body’s electrical signals, starting with heart rhythms. By leveraging a first of its kind combination of hardware and software, we deliver unprecedented cardiac signal clarity, ending the reliance on ‘mixed signals’ and ‘reading between the lines.’ Our platform technology is addressing some of healthcare’s biggest challenges—saving time, saving costs, and saving lives. The PURE EP™ Platform, an FDA 510(k) cleared non-invasive class II device, provides superior, real-time signal visualization allowing physicians to perform highly targeted cardiac ablation procedures with increased procedural efficiency. An innovation in one of the most critical areas of electrophysiology, PURE EP™ is revitalizing the value of the EGM, preserving elaborate cardiac signals in their original format— pure from beginning to end. Interested in joining our team? Check out our available opportunities by visiting: www.biosig.com/join-our-team.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Boehringer Ingelheim is a research-driven pharmaceutical company that strives to improve the health of people and animals worldwide. It was founded in 1885 and has since evolved into a global company with three business units: Human Pharma, Animal Health, and Biopharmaceuticals. The company is committed to innovation and diversity, with employees from over 170 countries and countless cultures.

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).

CaroGen Corporation is an emerging biopharmaceutical company with an entirely new vaccine platform technology developed at Yale University School of Medicine. The Company has recently executed an exclusive license with Yale University to the replication proficient virus-like vesicle (VLV) a platform technology for the development of vaccines for worldwide commercialization. The proprietary VLV technology which has been validated in a number of animal models including non-human primates will be employed to create new, potentially first-in-class vaccines that engage the body’s immune system to both recognize and fight off various diseases. Our vision is to control the spread of infectious diseases by using viral-based technology to produce recombinant protein nanoparticle vaccines for viruses, bacteria and parasites. We are dedicated to creating recombinant vaccines to address a broad range of infectious and chronic diseases. The company is developing a portfolio of vaccine candidates targeting hepatitis B virus, and potentially hepatitis C and other viral agents.

Cellinfinitybio is a biotechnology company that pioneers massive directed evolution to unlock the infinite potential of cell therapy.

CheminPharma is a biotechnology services company based in Woodbridge, CT. Founded in 2007, the main objective is to provide high-quality medicinal chemistry focused drug discovery services to biotechnology and pharmaceutical sector. In recent years, CheminPharma has expanded into other closely related businesses. CheminPharma's business rests on the following two pillar strategies: 1. Drug discovery research services 2. Novel Research tools & reagents We are looking to form partnerships with small molecule biotechnology and pharmaceutical companies where we can provide essential chemistry services to aid in the drug discovery process. If you are interested in a collaboration opportunity, feel free to contact us directly!

LEADING THE SUPPLY OF HIGH QUALITY GENERIC APIs 21st Century economic, social, technical and regulatory dynamics are dramatically changing the pharmaceutical world making it more challenging than ever to find profitable opportunities. That's why it's important to work with a supply-partner who knows how to navigate through the tough issues, help you overcome obstacles and get you to the market fast to gain competitive advantage. Established in 1982, ChemWerth is a full service generic drug development and supply company providing high quality API's to regulated markets worldwide. Through exclusive development and partnerships with API manufacturers, ChemWerth provides expertise in product selection, development, analytical and regulatory services, and strong project management to ensure the highest standards of quality. We are committed to providing our customers with a distinct competitive advantage. Our team of technical, analytical, regulatory and marketing experts can enhance your business by: 1. Advancing your product development; 2. Ensuring the manufacturing facilities we represent maintain a high level of compliance with ever-evolving cGMPs; 3. Collaborating with manufacturers in establishing appropriate protocols and methodologies to prepare a sound and complete DMF; 4. Sourcing APIs from China, India, Germany and the US to provide our customers with the best value; and 5. Advancing Paragraph IV filings through our exclusive API development and supply partnerships.

CooperSurgical is driven to advance the care of women, babies, and families around the world. We believe in empowering individuals and healthcare professionals in making health and life choices. We are trusted by clinicians worldwide for products, technologies, and services that support a wide range of reproductive solutions, from contraception to fertility and preventative and therapeutic gynecological care.

Cytogel is a clinical stage bio-pharmaceutical company developing first in class drug candidates from the novel endomorphin family of molecules, that target key pain pathways and alleviate pain. This groundbreaking approach is backed by new technology to deliver treatment to people in pain. Learn how we’re reinventing pain management.

Detect builds tools that empower people to understand their health and make informed, timely decisions. Led by Founder Dr. Jonathan Rothberg, the Detect team is redesigning the future of healthcare with the power of technology. Detect wants to make fast, accurate diagnostic testing as routine as taking your temperature and as accessible as telemedicine.

DIANT® offers break-through nanoparticle processing tools and services for a large variety of particle modalities. DIANT® Pharma’s system for continuous production overcomes the challenges of traditional batch processes by providing better control, scalability, real-time monitoring and feedback, regulatory acceptance, reduction in unit operations, and highquality outputs. Our proprietary continuous manufacturing system for nanoparticles has a widest array of applications within the biopharmaceutical and Cell/Gene Therapy industry.

DKP Genomics is a bioinformatics CRO. We provide top-quality computational biology analysis and bioinformatics infrastructure support to biotechnology, pharma, and agricultural companies and to research foundations. With nearly 15 years of experience in both biotech and major pharma, we're well versed in the standard analyses as well as advanced analyses to help identify targets, biomarkers, compound mechanisms, and advance the understanding of biological pathways and systems in multiple areas: microbial systems, diabetes / obesity, frailty, cancer, and neuroscience. More information can be found at http://www.dkpgenomics.com

Enrich Biosystems develops a highly integrated microfluidics-free high-throughput cell imaging/analysis/capture platform to accelerate cell-based biology and therapy discovery, precision medicine, and many other critical life science applications. Its bench-top instrument enables short and long-term studies of interactions between living cells. The need for these studies is extensive, including cancer, immunology, and stem cells, in activities ranging from pure research to human clinical therapies. Enrich technology was invented by scientists who were struggling with the complex workflow of monitoring cell/cell interactions using microfluidics-based tools. It is straightforward to use, providing a low-risk, affordable tool for any academic and industrial labs.

At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients by delivering superior, long-term outcomes compared to current anti-cancer therapies. We are pioneers who rapidly translate discoveries into innovations and innovations into differentiated therapeutic solutions, to address the most significant unmet medical needs in oncology.

GestVision Inc. is a biotechnology company that is committed to securing safer pregnancies by fearlessly challenging the status quo for women's health. We promise to deliver confidence to healthcare providers to make sound clinical decisions. Our aim is to address the unmet medical needs in women's health by bringing forth premium products based upon robust scientific discoveries.

Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today's precision cancer medicines. Using a novel ‘hold and kill' mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.

The Swoop® system brings MR brain imaging within reach. Our mission is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020. It is a portable ultra-low field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases.

InveniAI is pioneering AI and machine learning to map and identify breakthrough innovation across industries. Our platform, AlphaMeld, is an Artificial Intelligence (AI) based system that monitors millions of data points every day to identify signals for breakthrough events and provides a first mover advantage in detecting early signals of innovation. It combines human ingenuity and experience, with ceaseless, comprehensive and efficient machine learning that ensures no data point is missed in the pursuit of Alpha signals. AlphaMeld monitors developments daily across industries and rank orders them on their breakthrough potential. Visit www.inveniai.com for more details. Connect with us on Twitter: @Inveni_AI Careers: We are always on the lookout for talent to join our team at our US headquarters in Guilford, CT USA. We are not hiring at present. Please check back or contact us at +1 203 643 8002. Important Note on Our Hiring Process at InveniAI (inveniai) At InveniAI, we are committed to upholding the highest standards of transparency and integrity in everything we do. As part of our dedication to providing a fair and genuine hiring process, we would like to address a crucial matter. It has come to our attention that some individuals may be receiving fraudulent claims requesting money or personal information under the guise of being associated with InveniAI's hiring process. These unauthorized and fraudulent individuals are sending emails from domain names which are similar to our official domain name ‘inveniai.com’. When the recipient clicks on the domain name provided by the fraudulent individuals, they may be redirected to our website (www.inveniai.com). All individuals are requested not to communicate with any email id other than our official email id(s) that end with ‘@inveniai.com’. We want to make it clear that this is not how we operate, and we take this matter very seriously. Our Policy: No Course Registration: We want to emphasize that

Kleo is a biotechnology company that develops and commercializes therapeutics for the treatment of cancer and infectious diseases.

L2 is a biotechnology company based in New Haven, Connecticut, USA with focus on new small molecule therapeutics, vaccines, and diagnostics

LambdaVision is developing the first protein-based artificial retina to restore meaningful vision for patients who are blind or have lost significant sight.

Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer. Our approach centers on creating oncology medicines that unequivocally show early signs of clinical activity and will matter to patients. Loxo@Lilly is a global organization with team members in Boulder, Colorado; Indianapolis, Indiana; New York City, New York; San Diego, California; South San Francisco, California; Stamford, Connecticut; and Madrid, Spain.

Lumendi is dedicated to improving healthcare through the development and application of medical technology that reduces the level of patient intervention and procedure time, positively impacts recovery rates and outcomes, and decreases costs to the healthcare system. Our approach will enable clinicians to perform existing procedures more efficiently and usher in a new era of incisionless therapies to treat conditions that previously required abdominal surgery. Founded in December 2014, Lumendi holds a worldwide exclusive license to certain intellectual property developed by Minimally Invasive New Technologies (MINT), a joint program of Weill Cornell Medical College and New York-Presbyterian Hospital. In collaboration with MINT and other partners, Lumendi is developing devices to enable less invasive endolumenal procedures in the GI tract, primarily in the colon. These devices have the potential to replace many invasive laparoscopic and open surgical procedures currently performed in the hospital setting, and may also facilitate performance of these procedures in the outpatient setting. We're also working on additional less invasive techniques that can lead to better patient outcomes and make procedures easier and more comfortable for clinicians. We partner with leaders in healthcare to understand their needs and the needs of patients, and work to develop new solutions that will improve their lives.

MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life. Please visit mannkindcorp.com to learn more.

Restech offers minimally invasive tools to multiple specialties in order to accurately diagnose and manage reflux, and will continue to create solutions related to the complexity gastric related diseases. Restech’s tools are helping evolve the standard of care for patients with reflux, and fecal incontinence, providing physicians with the necessary data to transform the algorithm of care for tens of millions of patients.

Mitotherapeutix was created to take advantage of advancements in RNA chemistry and its use in developing siRNA based drugs that can target otherwise difficult to address disease targets. Our initial gene target is a novel protein that controls metabolic activity/efficiency in the mitochondria. The ability to control mitochondrial activity is significant because > 90% of the energy of the cell comes from the mitochondria. This gene target is a negative regulator. Thus, in the presence of the regulator, metabolism is slowed down and the removal of the regulator safely increases metabolism. We have explored the function of this metabolic regulator in different tissues and disease states and have found that turning off the regulator can have a positive effect in disease treatment. Targeting this gene product creates the opportunity of producing a drug that can treat a wide array of diseases.

MCRA is the leading global full-service medical device, diagnostics, and biologics CRO and consulting advisory firm. MCRA delivers to its client's industry experience, integrating its seven business value creators: regulatory, clinical research, reimbursement, healthcare compliance, quality assurance, due diligence and distribution logistics to provide a dynamic, market-leading effort from innovation conception to commercialization. MCRA's integrated application of these key value-creating initiatives provides unparalleled value for its clients. MCRA has offices in Washington, DC, Hartford, CT, New York, NY, London, England, Winterthur, Switzerland, Eschborn, Germany and Tokyo, Japan and serves nearly 1,000 clients globally. Its core focus areas of therapeutic experience include orthopedics, spine, biologics, cardiovascular, diagnostic imaging, wound care, artificial intelligence, dental, anesthesia, general surgery, digital health, neurology, robotics, oncology, general and plastic surgery, urology, and in vitro diagnostic (IVD) devices and medical device cybersecurity. MCRA places particular emphasis on its expertise working with companies in all stages of development and throughout the technology life cycle by ushering technologies from the conceptual pre-clinical stage to market approval.

NanoViricides, Inc. makesnanoviricides®. Nanoviricides are nanoparticles designed to protect cells from infection by acting as decoys. Virusesbind to nanoviricides instead of cell-surface receptors, gettrapped, and become neutralized.NanoViricides is working to developa treatment for COVID-19 using its nanoviricide®technology.

Neuvotion is developing breakthrough solutions for facilitating and restoring movement. Our approach combines targeted neurostimulation and AI (artificial intelligence) to deliver unparalleled therapeutic value for patients with a movement disorder or impairment from stroke or injury. Neuvotion products allow doctors and therapists to leverage state-of-the-art technology, while monitoring patient progress in-person or remotely.

With over 20 years of expertise, NorthEast BioAnalytical Laboratories LLC, also known as NorthEast BioLab, specializes in providing top-notch GLP and clinical bioanalytical services. We are proud to be trusted partners to hundreds of industry sponsors and renowned investigators in the biotechnology sector. We are an independent, full-service facility that adheres to GLP/GCLP compliance. Our FDA-audited and DEA & CT State Schedule II-IV approved facility is managed by Watson LIMS, ensuring seamless operations. Our dedicated scientists and project teams excel in assay development, optimization, troubleshooting, and full method validation on various platforms, including Ligand Binding Assays (ELISA, Meso Scale Discovery, Luminex, Western Blotting, etc.), Mass Spectrometry Liquid Chromatography (LC-MS/MS, HPLC-UV/DAD/Fluorescence, etc.), and Cell And Gene Therapy platforms (Cell-Based Assay, qPCR and dPCR). With our custom assay development services, we offer comprehensive solutions for pharmacokinetics analysis studies, toxicokinetic safety testing, immunogenicity assay, multiplex cytokine analysis, PD biomarker assessment, biochemical assay, mechanism of action, gene expression, copy number variation investigations, etc. Since its establishment in 2003, our team of dedicated biologists and chemists has been committed to empowering mission-driven biotech. With our vast experience and technical expertise, we deliver exceptional preclinical study and clinical assay development services as a Contract Research Organization (CRO). At NorthEast BioLab, we prioritize top quality and industry-leading turnaround time while offering highly competitive pricing. Our team is dedicated to helping you meet the stringent timelines of various milestones throughout your drug development life-cycle. SPEAK TO OUR SCIENTISTS today to expedite your bioanalytical assay development, validation, and sample analysis!

Founded in 1944, NSF is committed to protecting and improving human health and the environment on a global scale. NSF is an independent organization that facilitates standards development, product certification, testing, auditing, education and risk management for public health and the environment. Manufacturers, regulators and consumers alike look to NSF for the development of public health standards and certification that help protect the world's food, water, health and consumer products. Widely recognized for its scientific and technical expertise in the health and environmental sciences, NSF is a Pan American Health Organization/World Health Organization Collaborating Center on Food Safety, Water Quality and Indoor Environment. NSF operates more than 320,000 square feet of state-of-the-art laboratory space and serves 40,000 clients in more than 180 countries worldwide. Its 3,000 team members include microbiologists, toxicologists, chemists, engineers, and environmental and public health professionals. Visit us at www.nsf.org.

Our vision: "Cancer treatment in one dose."​ OncoSynergy is a patient-focused biotechnology startup spun out from UCSF and the JLABS South San Francisco incubator. Based in bustling Stamford, Connecticut (~40 mins from NYC), we are creating a new class of cancer medicines to maximize patient survival and quality of life with minimal side effects. We are a small, nimble startup team that launched our first clinical trial in 2020 for glioblastoma (aggressive brain cancer). While we are at the forefront of potential game changing research, please support our patients. They need you to spread awareness far and wide so that more research is being dedicated to devastating cancers like glioblastoma.

Perosphere Technologies is focused on bringing forth new, Point-of-Care (PoC) solutions that make diagnosis, treatment, and prevention a matter of actionable data. We bring the clarity and confidence needed to transform an incomplete clinical picture and drive the way decisions are made in coagulation.

Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools to help trial sponsors make quick and informed decisions to expedite drug development. Our distinguished team works side-by-side with its clients to analyze data, answer questions, and offer informed solutions to benefit study sponsors, investigators, and ultimately patients. Phesi has been applying its innovative technology and deep expertise to help life sciences companies for over 10 years. Our experts work with study sponsors to drive solutions from clinical development planning through trial implementation to optimize protocol designs, select the best investigator sites, shorten enrollment cycle times, select and manage CROs, and much more.

Plumcare is a healthcare company that provides real-world data for drug discovery and development, as well as DNA insights to empower families in managing their health.

Portage Biotech is a clinical-stage immuno-oncology company with a team of scientists, clinicians, and pharma-experienced executives who have a long history of success, collectively contributing to five oncology drug approvals. The company is focused on advancing multi-targeted therapies with the mission to expand the number of treatment options for cancer patients.

Since its inception in 2011, Precipio’s (NASDAQ: PRPO) vision is to battle the problem of cancer misdiagnosis, by developing innovative technologies that improve diagnostic accuracy and laboratory workflow, delivering better results to patients and their physicians. In addition to robust R&D and commercial departments developing and bringing to market its proprietary products, Precipio also operates a clinical laboratory that serves as a testing ground for company products from its development phase to full utilization within the clinical setting. Precipio’s Products Division develops, produces, and sells proprietary diagnostic products to laboratories. Precipio also has a Clinical Diagnostics Division which operates the company’s CLIA/CAP laboratory, servicing oncologist practices and hospitals to provide comprehensive diagnostic services, while utilizing the same technologies developed by the Products Division.

Purdue Pharma’s bankruptcy case was heard before the Supreme Court of the United States in December 2023. In June 2024, the Court voted 5-4 against third-party releases contained in the Plan of Reorganization. The decision does nothing to deter us from the twin goals of using settlement dollars for opioid abatement and turning the company into an engine for good. We are reaching back out to creditors and renewing our pursuit of a resolution that delivers billions of dollars of value for opioid abatement and allows the Company to emerge from bankruptcy as a company with a public-minded mission. The Supreme Court’s decision does not affect Purdue’s operational stability or our ability to produce medications safely and effectively. We continue to operate fully, honoring our existing relationships and meeting our obligations to our partners and customers. The company will continue serving patients who rely on our medicines, and working to introduce new medicines that will help save and improve lives.

Quantum-Si is a biotechnology company that focuses on genomics and medical devices.

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.

Recombinant Technologies, LLC, is an emerging biotechnology company focused on developing therapeutics for neurodegenerative diseases. This innovative Bio-Technology company will ... Plasma lipids and lipoprotein profile in coronary heart disease and in healthy volunteers in South ... Recombinant Technologies and life sciences research enabler and commercialization expert.

Spun out of Yale University in 2020, RIGImmune is a platform biopharmaceutical company developing a novel investigational class of RNA immunotherapies, and advancing complimentary targeted delivery systems, for the broad-spectrum treatment of viral diseases and cancer. Led by biopharma industry veteran, President Susan Sobolov, PhD, RIGImmune’s products act to specifically modulate RIG-I, a host surveillance pathway that triggers the innate immune system to enhance the patients’ intrinsic response to disease. RIGImmune was launched in 2020 by Yale Professors Anna Marie Pyle, PhD and Akiko Iwasaki, PhD, who are also Scientific Advisors for the company. Pyle co-discovered the RIG-I receptor family and conducted many of the first structural and biochemical investigations on RIG-I. Pyle is also a specialist in RNA structure, and design. In collaboration with Iwasaki, Pyle designed the stem loop RNAs for selective targeting of RIG-I using crystal structure data of RIG-I complexed with RNA and developed them as antitumor and anticancer compounds.

RNAConnect, Inc. is a company focused on the development of life science reagents to help further RNA sciences. They promise groundbreaking solutions for exploring the real-world diversity of RNA sequence and structure.

Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.

The SingleTimeMicroneedle Patch allows vaccines to be delivered via transdermal patch that painlessly embeds bodily degradable microneedles in the skin. The microneedles can be programmed for delivery over time and at specific times, requires no refrigeration, and can be self-administered by patients. The core technology of STM is a vaccine patch which can be painlessly applied at a single time on the skin to embed arrays of microneedles (MNs) inside the superficial skin layer (like an invisible tattoo). The MNs are made of a safe biodegradable polymer (used for surgical suture) and pre-programmed to release vaccines repeatedly over a long period, mimicking the effect of multiple prime/booster doses in the traditional vaccination process. The vaccines (including subunit protein-based antigen, vector-based vaccine or mRNAs) are stabilized against high temperatures, thus avoiding the need of cold-chain storage facilities and affirming the antigenicity for a long-term skin embedment. The technology will revolutionize the vaccination process by (1) enabling a high immunogenic efficacy via transdermal delivery, (2) enhancing patient compliance via the use of painless and self-administered skin patch, and (3) removing the logistic/economic burden to store vaccines at high temperatures. This skin patch could also be applied for animal vaccination, offering a high impact on both healthcare and other industry sectors.

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an investigational oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.

Thetis Pharmaceuticals is a clinical stage biopharmaceutical company developing a first-in-class, oral Resolvin E1 drug (TP-317) for treating mild-to-moderate inflammatory disorders. The company was founded in 2011 by ex-Pfizer R&D executives and healthcare investors.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.

TriRx Pharmaceutical Services is a leading global contract development and manufacturing organization (CDMO) that provides comprehensive solutions for the animal health and human pharmaceutical industries. TriRx provides integrated development, manufacturing, and supply services from our network of state-of-the-art facilities across the United States and Europe. Founded by industry veterans, TriRx understands what it means to outsource development and manufacturing of your drug product, and that we are committed to delivering CDMO services at a higher standard of performance. Built on honesty, openness, and integrity, TriRx gives our clients total access to our people and processes, treating your product like its own. TriRx is your partner for advancing products to market. We provide comprehensive development, manufacturing, and packaging capabilities from the clinical- to commercial-scale for both sterile and non-sterile pharmaceutical drug products. Our expertise spans a wide range of services and modalities including: - Biologics - Biotech API - Solid Dose - Drug Development - Analytical Testing - Solutions, Suspensions, and Colloidal Dispersions - Liquids, Creams, Ointments - Fill/Finish - Packaging - Aseptic Compounding - Animal Health Products TriRx maintains strict adherence to the regulatory standards required by the FDA, EMA, and other global health authorities. This, coupled with our rigorous quality control processes, ensures that every product we manufacture meets the highest quality standards. We are more than just a CDMO; we are a trusted partner in the pharmaceutical industry. Whether you are a startup biotech or a multinational pharmaceutical company, TriRx is dedicated to helping you achieve your objectives and bring vital medications to the markets and patients who need them most. Your Product. Your Facility. Your Team. A CDMO You Can Trust.

Ultimate Nutrition was founded in 1979 by Victor H. Rubino. At the time Victor was one of the top amateur power lifters in the United States. Driven by a goal to become the best, Victor knew that supplements were the key to improving his performance through increased strength and faster recovery. Not satisfied with the current supplements that were available to him the 1970's and being a biochemist himself, Victor decided to launch his own company. Thus, Ultimate Nutrition was born. Victor's goal was to create high quality, thoroughly researched products, while remaining at an affordable price for everyone. In the late 1970's and early 1980's Ultimate Nutrition was among the first companies to have Amino Acid tablets, protein powders, carbohydrate powders, and various types of Fat Burners. By the late 1980's and early 1990's Ultimate Nutrition launched several legendary products. By the mid 1990's Ultimate Nutrition again was on the cutting edge as one of the first companies to come out with Whey Protein powder in a bottle. Today, Ultimate Nutrition continues to excel with a wide range of products to meet consumer demand. Some of our most well known and loved products include ProStar® Whey, Iso Sensation® 93, Iso Mass Xtreme Gainer®, Muscle Juice® 2544, GlutaPure®, Ultra Ripped®, and Horse Power® X. Our cutting-edge R&D team has created new products like Pre Gold, Cheat Code, Gold Burn, NutriMEAL, JackT, Chicken Protein Isolate, Protein Fat Burner, Rice-Olate (rice protein), Clean Whey, Natural Gainz, and we launched our Vitality Series of healthy-aging products! Sadly, Victor Rubino passed away in March 2003 at 48 years young. However, Ultimate Nutrition is still owned and operated by the Rubino family to this day. Having built an international following, Ultimate Nutrition is proud to bring our beloved supplements to the U.S. market. Our commitment to Victor's vision remains the same, to create high quality, highly researched products at affordable prices.

Veradermics, Inc. is a medical dermatology company advancing first-in-class therapeutics that address real-world patient needs in under-innovated dermatology markets.

Virscio is a specialty translational research organization developing and providing innovative in vivo disease modeling and related preclinical research and development services to meet the preclinical, translational, and regulatory research needs of the pharmaceutical and life sciences industry. We specialize in the fields of ophthalmology, central nervous system, cardiovascular and metabolic related disease and disorders, and have advanced discovery and development programs for a wide range of sponsors, collaborators, and partners around the world, ranging from large pharmaceutical companies and venture-backed biotechnology companies to academic teams seeking to apply the most cutting edge research and development strategies in the most efficient and robust manner.

Virscio is a specialty translational research organization developing and providing innovative in vivo disease modeling and related preclinical research and development services to meet the preclinical, translational, and regulatory research needs of the pharmaceutical and life sciences industry. We specialize in the fields of ophthalmology, central nervous system, cardiovascular and metabolic related disease and disorders, and have advanced discovery and development programs for a wide range of sponsors, collaborators, and partners around the world, ranging from large pharmaceutical companies and venture-backed biotechnology companies to academic teams seeking to apply the most cutting edge research and development strategies in the most efficient and robust manner.

Wellinks is the COPD disease management company providing individuals with the personalized care and support necessary for successful self-management. We prioritize the unique needs of each member to establish a clear path to better health. Our programs extend the reach of existing care resources, and fill gaps where they are absent. Respiratory specialists and our health coaches work one-on-one and across a community of members to personalize the experience and unlock the power of the individual in their journey to better health. Our care pathways are supported by a suite of innovative and simple to use technology, including a kit of connected devices and the Wellinks app, bridging the gap between doctor visits and allow patients to manage their COPD from wherever life takes them. Wellinks provides a welcoming and inclusive environment where members trust they will receive the best possible care and guidance in managing their COPD. Our solution is intuitive, engaging, and fully integrated across the care journey — empowering patients with the peace of mind and freedom to live fully and breathe freely.

Wren Laboratories is revolutionizing cancer diagnostics with advanced machine learning and liquid biopsy mRNA-based technology. Our goal is to provide precise, non-invasive diagnostics tailored to each patient's unique molecular profile, transforming early detection and surveillance of cancer for better patient outcomes. With over 100 patents and validation from more than 60 clinical studies, Wren has developed highly sensitive liquid biopsy mRNA gene expression-based assays. These innovative assays aid in cancer diagnosis, detect minimal residual disease (MRD), and predict tumor prognosis and therapeutic response. Our tests, including the NETest for neuroendocrine tumors and PROSTest for prostate cancer, leverage mRNA technology and AI/ML genomic assays for unparalleled molecular insights. This allows accurate detection of cancer markers, empowering personalized care. Our mRNA-based diagnostics are crucial in monitoring patients post-surgery or treatment. Wren also offers Biopharma services with AI/ML liquid biopsy genomic assays for research and companion diagnostics (CDx) development. Our RNA stabilizer tubes preserve whole blood at ambient temperature for up to 10 days, reducing clinical trial logistics. From our CLIA-certified, CAP-accredited, and NYS-licensed lab, our tests ensure high accuracy and reliability. For more information, visit our website and follow us for updates in non-invasive cancer diagnostics.

For more than 300 years, Yale University has inspired the minds that inspire the world. Based in New Haven, Connecticut, Yale brings people and ideas together for positive impact around the globe. A research university that focuses on students and encourages learning as an essential way of life, Yale is a place for connection, creativity, and innovation among cultures and across disciplines.